{"id":15313,"date":"2022-11-08T07:00:10","date_gmt":"2022-11-08T06:00:10","guid":{"rendered":"https:\/\/www.sequanamedical.com\/?p=15313"},"modified":"2022-11-07T16:58:53","modified_gmt":"2022-11-07T15:58:53","slug":"sequana-medical-to-present-at-jefferies-london-healthcare-conference-2","status":"publish","type":"post","link":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/","title":{"rendered":"Sequana Medical to present at Jefferies London Healthcare Conference"},"content":{"rendered":"<p><strong>Ghent, Belgium \u2013 8 November 2022 \u2013 <\/strong><strong>Sequana Medical NV (Euronext Brussels: SEQUA, the &#8220;Company&#8221; or &#8220;Sequana Medical&#8221;)<\/strong>, a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to 17 November 2022.<\/p>\n<p>The Company will provide an update on its <strong>alfa<\/strong>pump\u00ae program, which has recently reported positive primary endpoint data from the North American pivotal POSEIDON study in recurrent or refractory ascites due to liver cirrhosis, enabling the filing of a Pre-Market Approval (PMA) application with the FDA, planned for H2 2023. The Company will also provide an update on DSR\u00ae (Direct Sodium Removal), its disease-modifying drug program for the treatment of heart failure, for which a US randomized controlled Phase 1b\/2a clinical study is planned to begin in H1 2023.<\/p>\n<p><strong>Details company presentation with live webcast<\/strong><\/p>\n<ul>\n<li>Thursday, 17 November 2022 at 10:55 am GMT \/ 11:55 am CET<\/li>\n<li>To register for the webcast, click <a href=\"https:\/\/wsw.com\/webcast\/jeff255\/sequa.br\/2382615\">here<\/a><\/li>\n<li>The presentation and a replay of the webcast will be available on Sequana Medical&#8217;s <a href=\"\/?page_id=5536\">Investors website<\/a> shortly after the event<\/li>\n<\/ul>\n<p>Registered investors can request a one-on-one meeting with Sequana Medical management via the online meeting platform of the conference or by contacting the Company at <a href=\"mailto:ir@sequanamedical.com\">IR@sequanamedical.com<\/a>.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>For more information, please contact:<\/strong><\/p>\n<p><strong>Sequana Medical<\/strong><\/p>\n<p>Lies Vanneste<\/p>\n<p>Director Investor Relations<\/p>\n<p>E: <a href=\"mailto:IR@sequanamedical.com\">IR@sequanamedical.com<\/a><\/p>\n<p>T: +32 (0)498 053579<\/p>\n<p><strong>Optimum Strategic Communications<\/strong><\/p>\n<p>Mary Clark, Nick Bastin, Vici Rabbetts<\/p>\n<p>E: <a href=\"mailto:Sequana@optimumcomms.com\">Sequana@optimumcomms.com<\/a><\/p>\n<p>T: +44 (0)7931 500 066<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>About Sequana Medical<\/strong><\/p>\n<p>Sequana Medical NV is a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. Fluid overload is a well-recognized problem in these growing diseases, causing severe problems for the large number of patients for whom current medicines are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life.<\/p>\n<p><strong>alfa<\/strong>pump\u00ae and DSR\u00ae are Sequana Medical\u2019s proprietary platforms that work with the body to remove this excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit <a href=\"https:\/\/www.sequanamedical.com\">www.sequanamedical.com<\/a>.<\/p>\n<p><strong><em>\u00a0<\/em><\/strong><\/p>\n<p><strong><em>Important Regulatory Disclaimers<\/em><\/strong><\/p>\n<p><em>The\u00a0<strong>alfa<\/strong>pump\u00ae system is currently not approved in the United States or Canada. In the United States and Canada, the\u00a0<strong>alfa<\/strong>pump system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see\u00a0<\/em><a href=\"https:\/\/www.poseidonstudy.com\/\"><em>www.poseidonstudy.com<\/em><\/a><em>. DSR\u00ae therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. DSR therapy is currently not approved for clinical research in the United States or Canada. There is no link between DSR therapy and ongoing investigations with the\u00a0<strong>alfa<\/strong>pump system in Europe, the United States or Canada. <\/em><\/p>\n<p><strong><em>Note:<\/em><\/strong><em> <strong>alfa<\/strong>pump\u00ae is a registered trademark. DSR\u00ae is a registered trademark in the Benelux, China, the EU, United Kingdom, and Hong Kong.<\/em><\/p>\n<p><strong><em>\u00a0<\/em><\/strong><\/p>\n<p><strong><em>Forward-looking statements<\/em><\/strong><\/p>\n<p><em>This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ghent, Belgium \u2013 8 November 2022 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA, the &#8220;Company&#8221; or &#8220;Sequana Medical&#8221;), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[74],"tags":[94],"class_list":["post-15313","post","type-post","status-publish","format-standard","hentry","category-persberichten","tag-niet-gereglementeerd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sequana Medical to present at Jefferies London Healthcare Conference - Sequana Medical<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sequana Medical to present at Jefferies London Healthcare Conference - Sequana Medical\" \/>\n<meta property=\"og:description\" content=\"Ghent, Belgium \u2013 8 November 2022 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA, the &#8220;Company&#8221; or &#8220;Sequana Medical&#8221;), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Sequana Medical\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/alfapump\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-08T06:00:10+00:00\" \/>\n<meta name=\"author\" content=\"Lies Vanneste\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SequanaMed\" \/>\n<meta name=\"twitter:site\" content=\"@SequanaMed\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\\\/\"},\"author\":{\"name\":\"Lies Vanneste\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/d19e52ba140d6e8fc2907b3b460e8ac3\"},\"headline\":\"Sequana Medical to present at Jefferies London Healthcare Conference\",\"datePublished\":\"2022-11-08T06:00:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\\\/\"},\"wordCount\":659,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"keywords\":[\"Niet-gereglementeerd\"],\"articleSection\":[\"Persberichten\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\\\/\",\"name\":\"Sequana Medical to present at Jefferies London Healthcare Conference - Sequana Medical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\"},\"datePublished\":\"2022-11-08T06:00:10+00:00\",\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"name\":\"Sequana Medical\",\"description\":\"Pioneer in the treatment of fluid overload\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sequanamedical.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\",\"name\":\"Sequana Medical NV\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"width\":396,\"height\":70,\"caption\":\"Sequana Medical NV\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/alfapump\",\"https:\\\/\\\/x.com\\\/SequanaMed\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sequana-medical\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/d19e52ba140d6e8fc2907b3b460e8ac3\",\"name\":\"Lies Vanneste\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"caption\":\"Lies Vanneste\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sequana Medical to present at Jefferies London Healthcare Conference - Sequana Medical","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/","og_locale":"nl_NL","og_type":"article","og_title":"Sequana Medical to present at Jefferies London Healthcare Conference - Sequana Medical","og_description":"Ghent, Belgium \u2013 8 November 2022 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA, the &#8220;Company&#8221; or &#8220;Sequana Medical&#8221;), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to [&hellip;]","og_url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/","og_site_name":"Sequana Medical","article_publisher":"https:\/\/www.facebook.com\/alfapump","article_published_time":"2022-11-08T06:00:10+00:00","author":"Lies Vanneste","twitter_card":"summary_large_image","twitter_creator":"@SequanaMed","twitter_site":"@SequanaMed","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/#article","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/"},"author":{"name":"Lies Vanneste","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/d19e52ba140d6e8fc2907b3b460e8ac3"},"headline":"Sequana Medical to present at Jefferies London Healthcare Conference","datePublished":"2022-11-08T06:00:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/"},"wordCount":659,"publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"keywords":["Niet-gereglementeerd"],"articleSection":["Persberichten"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/","url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/","name":"Sequana Medical to present at Jefferies London Healthcare Conference - Sequana Medical","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/#website"},"datePublished":"2022-11-08T06:00:10+00:00","inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-to-present-at-jefferies-london-healthcare-conference-2\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.sequanamedical.com\/#website","url":"https:\/\/www.sequanamedical.com\/","name":"Sequana Medical","description":"Pioneer in the treatment of fluid overload","publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sequanamedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.sequanamedical.com\/#organization","name":"Sequana Medical NV","url":"https:\/\/www.sequanamedical.com\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","contentUrl":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","width":396,"height":70,"caption":"Sequana Medical NV"},"image":{"@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/alfapump","https:\/\/x.com\/SequanaMed","https:\/\/www.linkedin.com\/company\/sequana-medical"]},{"@type":"Person","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/d19e52ba140d6e8fc2907b3b460e8ac3","name":"Lies Vanneste","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","caption":"Lies Vanneste"}}]}},"_links":{"self":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/15313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/comments?post=15313"}],"version-history":[{"count":0,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/15313\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/media?parent=15313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/categories?post=15313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/tags?post=15313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}